Cullinan Therapeutics Submits FDA Application for Zipalertinib Combination Therapy in Lung Cancer
Cullinan Therapeutics has initiated submission of a new drug application to the FDA for zipalertinib combined with chemotherapy to treat patients with untreated advanced lung cancer carrying specific EGFR mutations. The submission is being processed through the FDA's Real-Time Oncology Review program, with completion anticipated by the end of 2026. Phase 3 trial data showed the combination therapy achieved the longest median progression-free survival observed to date in this patient population.
Zipalertinib represents a targeted approach to treating a specific genetic subset of lung cancer patients. The drug is designed to address EGFR exon 20 insertion mutations, which occur in a small but meaningful patient population—roughly 12% of Americans with EGFR-mutated lung cancer carry this particular mutation. The combination therapy's performance in the Phase 3 REZILIENT3 trial suggests it may offer improved outcomes compared to chemotherapy alone for patients with advanced disease who have not yet received prior treatment.
The accelerated development pathway reflects the drug's potential medical importance. Cullinan is pursuing approval through the FDA's Real-Time Oncology Review program, which enables earlier assessment of preliminary data. Separately, a monotherapy application remains under standard review with a decision expected in early 2027, while the combination therapy application could advance through 2026.
If approved, zipalertinib could expand treatment options for patients with EGFR-mutated advanced lung cancer, particularly those with the exon 20 insertion variant who historically have faced limited alternatives. The drug's development may influence how oncologists approach first-line treatment decisions in this patient subset. Financial success could signal continued investment in targeted therapies for rare genetic cancer mutations. However, access and cost considerations may affect patient benefit realization, and real-world efficacy data would ultimately determine clinical impact.